The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin
Open accessAbstract
The oxazolidinones are a novel class of antibiotics that act by inhibiting protein synthesis. It as been reported that the drug exerts its primary activity on the initiation phase of translation. In order to study the possibility of direct interaction between the drug and the ribosome, we have developed a binding assay using 14C-labelled eperezolid (PNU-100592; formerly U-100592). Eperezolid binds specifically to the 50S ribosomal subunit of Escherichia coli. The specific binding of eperezolid is dose dependent and is proportional to the ribosome concentrations. Scatchard analysis of the binding data reveals that the dissociation constant (Kd) is about 20 microM. The binding of eperezolid to the ribosome is competitively inhibited by chloramphenicol and lincomycin. However, unlike chloramphenicol and lincomycin, eperezolid does not inhibit the puromycin reaction, indicating that the oxazolidinones have no effect on peptidyl transferase. In addition, whereas lincomycin and, to some extent, chloramphenicol inhibit translation termination, eperezolid has no effect. Therefore, we conclude that the oxazolidinones inhibit protein synthesis by binding to the 50S ribosomal subunit at a site close to the site(s) to which chloramphenicol and lincomycin bind but that the oxazolidinones are mechanistically distinct from these two antibiotics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
THE ATTRACTIONS OF PROTEINS FOR SMALL MOLECULES AND IONS
Scatchard, G. (1949) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1949.tb27297.x · Cited by 19,778
Brickner, S. J., Hutchinson, D. K., Barbachyn, M. R., Manninen, P. R., Ulanowicz, D. A., Garmon, S. A., Grega, K. C., Hendges, S. K., Toops, D. S., Ford, C. W., et al. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm9509556 · Cited by 582
Moazed, D., & Noller, H. F. (1987) · Biochimie · doi:10.1016/0300-9084(87)90215-x · Cited by 335
AMINO ACID TRANSFER FROM AMINOACYL-RIBONUCLEIC ACIDS TO PROTEIN ON RIBOSOMES OF ESCHERICHIA COLI
Nathans, D., & Lipmann, F. (1961) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.47.4.497 · Cited by 300
Ribosomes and protein synthesis : a practical approach
Spedding, G. (1990) · Oxford University Press eBooks · Cited by 203
Bacterial protein synthesis: The effects of antibiotics
Cundliffe, E., & McQuillen, K. (1967) · Journal of Molecular Biology · doi:10.1016/0022-2836(67)90249-5 · Cited by 167
Fernández-Muñoz, R., Monro, R. E., Vázquez, D., & Torres‐Pinedo, R. (1971) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1971.tb01607.x · Cited by 145
Mechanism of action of DuP 721: inhibition of an early event during initiation of protein synthesis
Eustice, D. C., Feldman, P., Zajac, I., & Slee, A. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.8.1218 · Cited by 118
Interaction of the antibiotics clindamycin and lincomycin withEscherichia coli23S ribosomal RNA
Douthwaite, S. R. (1992) · Nucleic Acids Research · doi:10.1093/nar/20.18.4717 · Cited by 87
Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound
Daly, J. S., Eliopoulos, G. M., Willey, S., & Moellering, R. C. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.9.1341 · Cited by 71
Cited by
Vancomycin-Resistant Enterococci
Cetinkaya, Y., Falk, P., & Mayhall, C. G. (2000) · Clinical Microbiology Reviews · doi:10.1128/cmr.13.4.686 · Cited by 1,163
Principles for targeting RNA with drug-like small molecules
Warner, K. D., Hajdin, C. E., & Weeks, K. M. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.93 · Cited by 749
Targeting RNA with Small Molecules
Thomas, J. R., & Hergenrother, P. J. (2008) · Chemical Reviews · doi:10.1021/cr0681546 · Cited by 647
The Oxazolidinone Linezolid Inhibits Initiation of Protein Synthesis in Bacteria
Swaney, S. M., Aoki, H., Ganoza, M. C., & Shinabarger, D. L. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.12.3251 · Cited by 555
Oxazolidinone Structure–Activity Relationships Leading to Linezolid
Barbachyn, M. R., & Ford, C. W. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200200528 · Cited by 553
Linezolid: The First Oxazolidinone Antimicrobial
Moellering, R. C. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-2-200301210-00015 · Cited by 455
Oxazolidinones: activity, mode of action, and mechanism of resistance
Bozdogan, B., & Appelbaum, P. C. (2004) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2003.11.003 · Cited by 403
Diekema, D. J., & Jones, R. N. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06964-1 · Cited by 378
Streptogramins, Oxazolidinones, and Other Inhibitors of Bacterial Protein Synthesis
Mukhtar, T. A., & Wright, G. D. (2005) · Chemical Reviews · doi:10.1021/cr030110z · Cited by 371
Toh, S., Xiong, L., Arias, C. A., Villegas, M. V., Lolans, K., Quinn, J., & Mankin, A. S. (2007) · Molecular Microbiology · doi:10.1111/j.1365-2958.2007.05744.x · Cited by 338
“Linezolid inhibits protein synthesis by binding to the large ribosomal subunit (Lin et al., 1997).”
BackgroundLinezolid: The First Oxazolidinone Antimicrobial
Paterson, D. L., Pasculle, A. W., & McCurry, K. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-10-200311180-00017 · Cited by 328
The A-Z of bacterial translation inhibitors
Wilson, D. N. (2009) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409230903307311 · Cited by 322
Wilson, D. N., Schluenzen, F., Harms, J. M., Starosta, A. L., Connell, S. R., & Fucini, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804276105 · Cited by 318
Antimicrobial Resistance to Linezolid
Meka, V. G., & Gold, H. S. (2004) · Clinical Infectious Diseases · doi:10.1086/423841 · Cited by 309
Prystowsky, J., Siddiqui, F., Chosay, J., Shinabarger, D. L., Millichap, J., Peterson, L. R., & Noskin, G. A. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.7.2154-2156.2001 · Cited by 302
Mechanisms of action of newer antibiotics for Gram-positive pathogens
Hancock, R. E. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70051-7 · Cited by 295
New approaches for treating staphylococcal biofilm infections
Kiedrowski, M. R., & Horswill, A. R. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06281.x · Cited by 288
The Site of Action of Oxazolidinone Antibiotics in Living Bacteria and in Human Mitochondria
Leach, K. L., Swaney, S. M., Colca, J. R., McDonald, W. G., Blinn, J. R., Thomasco, L. M., Gadwood, R. C., Shinabarger, D., Xiong, L., & Mankin, A. S. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.04.005 · Cited by 276
Linezolid: A Review of its Use in the Management of Serious Gram-Positive Infections
Perry, C. M., & Jarvis, B. (2001) · Drugs · doi:10.2165/00003495-200161040-00008 · Cited by 275
Inhibition of Mammalian Mitochondrial Protein Synthesis by Oxazolidinones
McKee, E. E., Ferguson, M., Bentley, A. T., & Marks, T. A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01411-05 · Cited by 270
Mendes, R. E., Deshpande, L. M., & Jones, R. N. (2014) · Drug Resistance Updates · doi:10.1016/j.drup.2014.04.002 · Cited by 221
Marks, J., Kannan, K., Roncase, E. J., Klepacki, D., Kefi, A., Orelle, C., Vázquez-Laslop, N., & Mankin, A. S. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1613055113 · Cited by 159
Mutations outside the anisomycin-binding site can make ribosomes drug-resistant
Blaha, G., Gürel, G., Schroeder, S. J., Moore, P. B., & Steitz, T. A. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.03.075 · Cited by 88
Metadata
- Authors
- Lin, A. H., Murray, R. W., Vidmar, T. J., & Marotti, K. R.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1997-10
- Volume
- 41
- Issue
- 10
- Pages
- 2127-2131
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2119704253
- Cited by
- 261
- References
- 14
- FWCI
- 3.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.